GT Biopharma Inc (GTBP)

[WordUP]

Right now investors seem to be favoring smaller biotech companies. The performance of the market-cap-weighted iShares Nasdaq Biotechnology ETF gained 30% over the past 12 months, and the equal-weighted SPDR S&P Biotech ETF climbed 54% during the same period. Similar to the market a few years ago, it was the investors who found opportunity in discounted biotech stocks who saw some of the biggest profit potential over the last few decades. Now it may only be a matter of connecting the dots with some of the biotechnology sector’s biggest names in order to point to the next opportunity that could be presenting itself right now.